GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synaptogenix Inc (NAS:SNPX) » Definitions » EV-to-EBIT

Synaptogenix (Synaptogenix) EV-to-EBIT : 3.07 (As of Jun. 05, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Synaptogenix EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Synaptogenix's Enterprise Value is $-21.77 Mil. Synaptogenix's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-7.08 Mil. Therefore, Synaptogenix's EV-to-EBIT for today is 3.07.

The historical rank and industry rank for Synaptogenix's EV-to-EBIT or its related term are showing as below:

SNPX' s EV-to-EBIT Range Over the Past 10 Years
Min: -7.42   Med: 0   Max: 8.75
Current: 3.07

During the past 5 years, the highest EV-to-EBIT of Synaptogenix was 8.75. The lowest was -7.42. And the median was 0.00.

SNPX's EV-to-EBIT is ranked better than
60.71% of 425 companies
in the Biotechnology industry
Industry Median: 9.61 vs SNPX: 3.07

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Synaptogenix's Enterprise Value for the quarter that ended in Mar. 2024 was $-22.36 Mil. Synaptogenix's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-7.08 Mil. Synaptogenix's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 31.68%.


Synaptogenix EV-to-EBIT Historical Data

The historical data trend for Synaptogenix's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synaptogenix EV-to-EBIT Chart

Synaptogenix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- -0.16 -1.83 1.63 2.68

Synaptogenix Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.72 1.57 1.85 2.68 3.16

Competitive Comparison of Synaptogenix's EV-to-EBIT

For the Biotechnology subindustry, Synaptogenix's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synaptogenix's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synaptogenix's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Synaptogenix's EV-to-EBIT falls into.



Synaptogenix EV-to-EBIT Calculation

Synaptogenix's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-21.771/-7.083
=3.07

Synaptogenix's current Enterprise Value is $-21.77 Mil.
Synaptogenix's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Synaptogenix  (NAS:SNPX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Synaptogenix's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-7.083/-22.3569375
=31.68 %

Synaptogenix's Enterprise Value for the quarter that ended in Mar. 2024 was $-22.36 Mil.
Synaptogenix's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Synaptogenix EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Synaptogenix's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Synaptogenix (Synaptogenix) Business Description

Traded in Other Exchanges
N/A
Address
1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
Executives
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Robert Weinstein officer: Chief Financial Officer 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Bruce Bernstein director 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Jonathan Schechter director C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
William S. Singer director C/O KIRKLAND & ELLIS LLP, 300 NORTH LASALLE, CHICAGO IL 60654
Daniel L. Alkon director, officer: Chief Scientific Officer C/O NEUROTROPE, INE., 205 EAST 42ND STREET - 20TH FLOOR, NEW YORK NY 10017
Alan J Tuchman director, officer: Chief Executive Officer 18 SYCAMORE ROAD, MAHOPAC NY 10541
George Perry director C/O NEUROTROPE, INC., 205 EAST 42ND STREET, 17TH FLOOR, NEW YORK NY 10010

Synaptogenix (Synaptogenix) Headlines

From GuruFocus

Synaptogenix to Present at the Cell Symposium

By PRNewswire PRNewswire 05-27-2022